{
  "id": 19187102,
  "title": "Eli Lilly's Foundayo Cuts Sleep Apnea Severity By Up To 44% In Phase 3 Trials",
  "url": "https://urgent.news/2026/11/09/eli-lillys-foundayo-cuts-sleep-apnea-severity-by-up-to-44-in-phase-3",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-09T17:41:02.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/eli-lillys-foundayo-cuts-sleep-apnea-severity-44-phase-3-trials"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Eli Lilly and Company (LLY) on Monday announced positive Phase 3 results showing that its oral obesity drug Foundayo (orforglipron) significantly reduced obstructive sleep apnea (OSA) severity in adults with obesity or overweight.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Seeking Alpha News",
        "title": "Eli Lilly releases Foundayo sleep apnea data",
        "url": "https://urgent.news/2026/11/09/eli-lilly-releases-foundayo-sleep-apnea-data",
        "published": "2026-11-09T16:39:05.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}